Corebridge Financial Inc. Has $9.74 Million Stock Position in Cencora, Inc. (NYSE:COR)

Corebridge Financial Inc. lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 4.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 43,369 shares of the company’s stock after selling 1,835 shares during the period. Corebridge Financial Inc.’s holdings in Cencora were worth $9,744,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora in the fourth quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC raised its position in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after acquiring an additional 69 shares during the last quarter. Kentucky Trust Co acquired a new position in shares of Cencora in the fourth quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,675 shares of company stock worth $8,034,778. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Finally, Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Price Performance

COR stock opened at $271.32 on Thursday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $271.86. The stock has a market capitalization of $52.61 billion, a PE ratio of 38.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company’s 50-day moving average is $252.47 and its 200-day moving average is $240.68. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.81%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.